Search
Hyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.
Products: HYLASE® DESSAU 150 IU, HYALASE POWDER FOR INJECTION 1500 iu/ampouleRacepinephrine
go.drugbank.com/drugs/DB11124ApprovedRacepinephrine is a racemic mixture consisting of d-[DB00668] and l-[DB00668] enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. … It is an active ingredient in oral inhalation over-the-counter products as racepinephrine hydrochloride.
Mercaptopurine
go.drugbank.com/drugs/DB01033ApprovedInvestigationalIt interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. … An antimetabolite antineoplastic agent with immunosuppressant properties.
Amitraz
go.drugbank.com/drugs/DB11373ExperimentalVet approvedIts insecticide effect is due to its agonistic activity in the alpha-adrenergic system, its interaction with the octopamine receptors in the central nervous system and its driven inhibition of the synthesis … It was generated in 1969 by the Boots Co. in England. Amitraz presents insect repellent effects and hence, it can be used as an insecticide and pesticide.
Synonyms: 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene, N,N'-(methyliminodimethylidyne)bis-2,4-xylidineCategories: Compounds used in a research, industrial, or household settingCarfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Olodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalSingle doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. … Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Clobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974. … [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Synonyms: Clobetasol propionate EInternational brands: Embeline EMersalyl
go.drugbank.com/drugs/DB09338ExperimentalThe sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577]. … Interestingly, it has been found to have antiviral properties in mice [L1584].
Sitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnIn 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. … Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.
Tigecycline
go.drugbank.com/drugs/DB00560ApprovedInvestigationalFood and Drug Administration (FDA) on June 17, 2005. … It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S.